Compass Therapeutics (NASDAQ:CMPX – Get Rating) and argenx (NASDAQ:ARGX – Get Rating) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
This is a breakdown of current ratings and recommmendations for Compass Therapeutics and argenx, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Compass Therapeutics presently has a consensus target price of $9.05, suggesting a potential upside of 186.39%. argenx has a consensus target price of $454.24, suggesting a potential upside of 12.69%. Given Compass Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Compass Therapeutics is more favorable than argenx.
Insider & Institutional Ownership
This table compares Compass Therapeutics and argenx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Compass Therapeutics and argenx’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Compass Therapeutics||N/A||N/A||-$39.22 million||($0.36)||-8.75|
|argenx||$445.27 million||50.40||-$709.59 million||($9.29)||-43.39|
Compass Therapeutics has higher earnings, but lower revenue than argenx. argenx is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Compass Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
Compass Therapeutics beats argenx on 8 of the 12 factors compared between the two stocks.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.